KOSPISemiconductors011690

Y2 Solution

₩2,595▲ 0.58%2026-11-18 close
Market Cap
₩95.2B
Turnover
₩300M
Volume
110K
Shares out.
36.7M
PER
—
PBR
0.9×
EPS
-₩169
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue Surges, Profit Base Still Thin

Bio-energy growth has lifted quarterly revenue sharply in 2026, but operating profit is still small and net results have swung from quarter to quarter.

  1. 1

    Q3 2026 revenue was KRW 114.6 billion, up 145.8% year on year, and operating profit of KRW 880 million turned positive from a year earlier.

  2. 2

    FY2025 posted an operating loss of KRW 2.57 billion and a net loss attributable to controlling shareholders of KRW 9.59 billion, after a profit of KRW 6.58 billion in 2024.

  3. 3

    Bio-energy revenue for the first nine months of 2026 reached KRW 204.6 billion, up 734.3% year on year, which the company said exceeds 70% of consolidated revenue.

  4. 4

    Net loss attributable to controlling shareholders totaled KRW 6.19 billion over the last four quarters, and Q2 2026 was the only one of those quarters with a profit of KRW 448 million.

  5. 5

    The bio unit's LUXA is running Phase 1/2a trials of a cell therapy for dry age-related macular degeneration, with the company targeting topline data within 2026.

02

Business structure

Y2 Solution was founded in 1976 and built its core business around the development and manufacture of power supply units (PSUs); it listed on the main board in 1995. The business now spans four areas: PSUs, bio-energy, robotics and bio drug development.

The PSU segment centers on power modules for electric-vehicle fast chargers and ultra-slim, high-output power technology for OLED and QNED TVs, and the company describes it as its stable earnings base.

The bio-energy segment distributes bio-diesel feedstock such as soybean oil, corn oil, waste cooking oil and animal fats; it began in the second half of 2025 and has supplied marine fuel to a major domestic refiner since the second quarter of 2026.

Cumulative bio-energy revenue for the first nine months of 2026 reached KRW 204.6 billion, which the company said exceeds 70% of consolidated revenue, according to its November 17, 2026 announcement.

The robotics segment grew after the subsidiary acquired last year was consolidated, and robotics and other segment revenue for the first nine months was KRW 4.1 billion, up 629.6% year on year.

Building on its PSU design and manufacturing capability, the company is developing an ultra-low-floor autonomous mobile robot (AMR) platform and upgrading next-generation drive systems with a partner.

The bio segment centers on LUXA, a US joint venture in which Y2 Solution holds a 50% stake, developing a cell therapy for dry age-related macular degeneration. The therapy has received RMAT designation from the US FDA and is in Phase 1/2a trials.

Bio-energy customers include major domestic and overseas petrochemical producers, and tighter European environmental policy and rising demand for renewable feedstock are cited as demand drivers.

Revenue mix is tilting toward bio-energy, while profitability depends on the balance between PSU earnings and the cost of new-business investment.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩46.6B-₩900M−2.0%
2025Q4₩48.3B-₩1.2B−2.4%
2026Q1₩86.7B₩1B1.1%
2026Q2₩87.4B₩700M0.8%
2026Q3₩114.6B₩900M0.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩120.5B₩1.8B-₩2.2B1.5%−2.7%53.5%
2023₩136.9B₩1.9B-₩300M1.4%−0.3%21.7%
2024₩154.5B₩2.9B₩6.6B1.9%6.1%15.0%
2025₩165.1B-₩2.6B-₩9.6B−1.6%−9.7%49.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual revenue rose from KRW 120.5 billion in 2022 to KRW 136.9 billion in 2023, KRW 154.5 billion in 2024 and KRW 165.1 billion in 2025, marking three consecutive years of growth from 2023 through 2025.

Growth slowed from 13.6% in 2023 and 12.8% in 2024 to 6.8% in 2025, and 2025 was the largest year within the 2022 to 2025 period.

Operating profit moved from KRW 1.78 billion in 2022 to KRW 1.91 billion in 2023 (up 7.0%) and KRW 2.89 billion in 2024 (up 51.3%), before swinging to an operating loss of KRW 2.57 billion in 2025. The operating margin fell from 1.9% in 2024 to -1.6% in 2025, so revenue growth did not carry through to profitability.

Net income attributable to controlling shareholders went from a loss of KRW 2.21 billion in 2022 and a smaller loss of KRW 345 million in 2023 to a profit of KRW 6.58 billion in 2024, then back to a loss of KRW 9.59 billion in 2025.

The debt ratio, defined as total liabilities over total equity, rose to 49.9% at the end of 2025 from 15.0% in 2024, with total liabilities of KRW 49.4 billion against total equity of KRW 99 billion.

Operating cash flow was -KRW 2.45 billion in 2022, -KRW 20.4 billion in 2023, KRW 10 billion in 2024 and -KRW 2.01 billion in 2025, showing wide swings.

Quarterly revenue went from KRW 46.6 billion in Q3 2025 to KRW 48.3 billion in Q4 2025, KRW 86.7 billion in Q1 2026, KRW 87.4 billion in Q2 2026 and KRW 114.6 billion in Q3 2026, rising in four consecutive quarters.

Operating profit was KRW 954 million in Q1 2026, KRW 665 million in Q2 (down 30.3% quarter on quarter) and KRW 880 million in Q3, with the Q3 figure turning positive from a year earlier.

Net loss attributable to controlling shareholders totaled KRW 6.19 billion over the last four quarters, with the Q4 2025 loss of KRW 4.52 billion the largest in that stretch.

The company attributed part of the 2025 net loss to derivative valuation losses on convertible bonds as the share price rose, noting that no actual cash outflow occurred.

05

Industry analysis

End demand for the PSU segment spans electric-vehicle fast chargers and high-output display power.

According to the company profile, Y2 Solution is investing to secure the market for ultra-slim, high-output PSUs for OLED and QNED TVs, and is strengthening competitiveness through power module development for EV chargers.

Bio-energy demand rests on tighter European environmental policy and rising demand for renewable feedstock, and the company said it secured a distribution network in the region in the first quarter of 2026.

Bio-diesel feedstock distribution is an intermediary business that needs sourcing and buyers to align at the same time. The robotics segment is anchored in physical AI and ultra-low-floor AMR development, combining power technology with robot drive systems.

The bio segment's dry AMD therapy is still in clinical stages and remains before commercialization, and public disclosures offer a limited basis for comparison with peers at a similar development stage.

On the cycle, bio-energy began in the second half of 2025, so its quarterly record is short, while PSUs are a longer-established manufacturing business.

Companies in the same sector classification, such as Samsung Electronics, SK hynix and HANMI Semiconductor, sell different products to different customers, so direct comparison is difficult. The company's stated differentiation is extending its PSU design and manufacturing capability into robotics and bio-energy.

06

Outlook

In early 2026 the company said it planned to grow bio-energy revenue to at least KRW 200 billion for the year, and cumulative bio-energy revenue of KRW 204.6 billion for the first nine months of 2026 has already passed that level.

Whether the revenue target translates into operating margin improvement at the same pace is a separate question, and the annual operating margin is the key checkpoint. The company aims to complete Phase 1/2a trials of LUXA's dry AMD cell therapy and secure topline data within 2026.

LUXA recently signed a contract with a global CDMO company to develop commercial manufacturing processes for its cryopreserved cell therapy. In robotics, the company targets public unveiling of an ultra-low-floor AMR prototype within 2026.

It plans to internalize a dedicated AMR power module by applying its charger power module and PSU design capability, seeking synergy across businesses. At its February 2026 announcement, the company said it would pursue profitability improvement this year on the back of bio-energy revenue growth.

Based on last year's timing, the 2026 annual results may come out in early 2027. The 2026 annual report is due by the end of March 2027, when segment revenue and any derivative valuation effects can be checked.

07

Valuation

PER
—
PBR
0.9×
ROE
-6.2%
EPS
-₩169
BPS
₩2,682
Dividend per share
₩0

Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits below 1x, so the stock trades at no premium to net asset value.

The company posted a profit attributable to controlling shareholders in 2024 but returned to a loss in 2025, which breaks the earnings-based trend. No cash dividend has been confirmed, and on a dividend basis the stock sits below the industry average.

Total equity and the equity attributable to controlling shareholders were both KRW 99 billion at the end of 2025, which makes asset-based measures comparatively more relevant.

Quarterly operating profit entered positive territory in 2026, but net results attributable to controlling shareholders have alternated by quarter, so earnings recovery is visible only as a direction. Valuation losses on convertible bonds move net income as the share price changes.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Bio-energy has scaled the top line

Cumulative bio-energy revenue for the first nine months of 2026 reached KRW 204.6 billion, up 734.3% year on year. The company said the business accounts for more than 70% of consolidated revenue in its November 17, 2026 announcement.

Q3 2026 consolidated revenue of KRW 114.6 billion, up 145.8% year on year, confirms the expansion on a quarterly basis. Revenue sources are broadening beyond the single PSU axis, which is the main bullish factor.

Quarterly operating profit has turned positive

Operating profit was KRW 954 million in Q1 2026, KRW 665 million in Q2 and KRW 880 million in Q3, so the quarterly operating result has stayed positive through 2026. Q3 2026 operating profit turned positive from a year earlier.

The direction of quarterly operating results has changed since the operating loss of KRW 938 million in Q3 2025.

Robotics and bio remain as options

Robotics and other segment revenue for the first nine months of 2026 reached KRW 4.1 billion, up 629.6% year on year. LUXA holds RMAT designation from the FDA, and the company targets topline data from its Phase 1/2a trial within 2026.

The company also set a target to unveil an ultra-low-floor AMR prototype within the year. Whether these two milestones materialize is the point at which new-business contribution can be measured.

09

Bear factors

Operating profit base is still small

The operating margin for 2025 was -1.6%, with the business swinging to an operating loss. Consolidated operating profit for the first nine months of 2026 was KRW 2.5 billion, smaller than the KRW 5.3 billion operating profit of the bio-energy unit over the same period.

Net losses attributable to controlling shareholders over the last four quarters totaled KRW 6.19 billion, so revenue growth has not fully carried into earnings.

Revenue leans on one short-history business

Bio-energy now accounts for more than 70% of consolidated revenue, yet the business only started in the second half of 2025, so its quarterly record is short. Operating profit in Q2 2026 fell 30.3% from the prior quarter.

Revenue growth has not prevented quarterly operating profit from moving sharply, which is the main bearish factor.

Net income is highly volatile

The 2025 net loss attributable to controlling shareholders of KRW 9.59 billion reversed a profit of KRW 6.58 billion in 2024. The company explained that derivative valuation losses on convertible bonds were reflected. Q3 2026 still recorded a net loss attributable to controlling shareholders of KRW 1.47 billion.

10

Risk factors

Concentration and policy dependence

Bio-energy revenue depends on European environmental policy and demand for renewable feedstock. If policy shifts or demand slows, a large share of consolidated revenue could be affected. Volume grew through newly secured customers, so changes in the customer mix are also a variable for revenue stability.

Clinical and development risk

LUXA's dry AMD cell therapy is in Phase 1/2a trials and remains before commercialization. Topline results within 2026 could differ from expectations. If the clinical timeline slips, preparation for commercial manufacturing could slip as well.

Financial and accounting volatility

Changes in the value of convertible bonds are booked as derivative valuation gains or losses, which move net income. The debt ratio rose to 49.9% at the end of 2025 from 15.0% in 2024. Operating cash flow was -KRW 2.01 billion in 2025, an outflow.

11

What to watch next

  1. By December 2026

    Whether topline data from the Phase 1/2a trial of LUXA's dry AMD cell therapy are released. The results form the basis of the commercialization strategy.

  2. By December 2026 (company target)

    Whether the ultra-low-floor AMR prototype is unveiled. It is the point at which PSU technology applied to robot drive systems can be verified.

  3. Early February 2027 (based on last year's timing)

    Announcement of 2026 annual revenue and operating results. It is the point at which the annual contribution of bio-energy and whether operating profit stays positive can be checked.

  4. By end of March 2027 (statutory deadline)

    The 2026 annual report. It is the point at which the annual operating margin, segment revenue and the effect of convertible bond valuation can be confirmed from filed results.

12

Overall view

Y2 Solution is in a phase of scaling its top line by adding bio-energy, robotics and bio businesses to its PSU core. Q3 2026 revenue of KRW 114.6 billion marked four consecutive quarters of growth, and cumulative bio-energy revenue of KRW 204.6 billion makes up a large share of the total.

On the other side, the 2025 operating loss of KRW 2.57 billion and net loss attributable to controlling shareholders of KRW 9.59 billion show that the profit base is still thin.

Quarterly operating profit in 2026 sits in positive territory but at roughly KRW 600 million to KRW 1 billion a quarter, and net losses attributable to controlling shareholders over the last four quarters totaled KRW 6.19 billion.

On the financial side, the debt ratio rose to 49.9% at the end of 2025 and total equity stands at KRW 99 billion. LUXA's trial results and the unveiling of the AMR prototype are business events that could be confirmed within 2026.

The next checkpoints on earnings are the 2026 annual operating margin and segment revenue in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. etoday.co.kr
  2. view.asiae.co.kr
  3. widedaily.com
  4. comp.wisereport.co.kr
  5. view.asiae.co.kr
  6. m.news.nate.com
  7. bloter.net
  8. newspim.com
  9. m.news.nate.com
  10. investing.com
  11. newspim.com
  12. comp.fnguide.com
  13. investing.com
  14. mt.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis